Mobile

A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors

Mise à jour : Il y a 4 ans
Référence : NCT01724320

Femme et Homme

Extrait

The purpose of this study is to determine the recommended dose (RD) for further phase II studies, of the Galectin-1 inhibitor OTX008 given subcutaneously in patients with advanced solid tumors

Critère d'inclusion

  • Solid Tumors

Liens